Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 21

1.

Twenty-five-year trends in myocardial infarction attack and mortality rates, and case-fatality, in six European populations.

Dégano IR, Salomaa V, Veronesi G, Ferriéres J, Kirchberger I, Laks T, Havulinna AS, Ruidavets JB, Ferrario MM, Meisinger C, Elosua R, Marrugat J; Acute Myocardial Infarction Trends in Europe (AMITIE) Study Investigators.

Heart. 2015 Sep;101(17):1413-21. doi: 10.1136/heartjnl-2014-307310. Epub 2015 Apr 8.

PMID:
25855798
2.

Treatment of anemia with darbepoetin alfa in systolic heart failure.

Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, Maggioni AP, McMurray JJ, O'Connor C, Pfeffer MA, Solomon SD, Sun Y, Tendera M, van Veldhuisen DJ; RED-HF Committees; RED-HF Investigators.

N Engl J Med. 2013 Mar 28;368(13):1210-9. doi: 10.1056/NEJMoa1214865. Epub 2013 Mar 10.

3.

Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF).

McMurray JJ, Anand IS, Diaz R, Maggioni AP, O'Connor C, Pfeffer MA, Solomon SD, Tendera M, van Veldhuisen DJ, Albizem M, Cheng S, Scarlata D, Swedberg K, Young JB; RED-HF Committees Investigators.

Eur J Heart Fail. 2013 Mar;15(3):334-41. doi: 10.1093/eurjhf/hfs204. Epub 2013 Jan 17.

4.

Trends in incidence, attack rate, and mortality of acute myocardial infarction in Estonia: the Tallinn AMI Registry 1991-2005.

Laks T, Jõeste E, Pullisaar O, Mäeots E, Lapidus I, Pietilä A, Salomaa V.

Ann Med. 2013 Mar;45(2):107-11. doi: 10.3109/07853890.2011.645380. Epub 2012 Jan 24.

PMID:
22273499
5.

Lung dysfunction of chronic smokers with no signs of COPD.

Nagelmann A, Tonnov Ä, Laks T, Sepper R, Prikk K.

COPD. 2011 Jun;8(3):189-95. doi: 10.3109/15412555.2011.565090. Epub 2011 Apr 22.

PMID:
21513442
6.

Prognostic impact of electrocardiographic signs in patients with Type 2 diabetes and cardiovascular disease: results from the PROactive study.

Pfister R, Cairns R, Erdmann E, Schneider CA; PROactive investigators.

Diabet Med. 2011 Oct;28(10):1206-12. doi: 10.1111/j.1464-5491.2011.03281.x.

PMID:
21388447
7.
8.

Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08).

Erdmann E, Charbonnel B, Wilcox RG, Skene AM, Massi-Benedetti M, Yates J, Tan M, Spanheimer R, Standl E, Dormandy JA; PROactive Investigators.

Diabetes Care. 2007 Nov;30(11):2773-8. Epub 2007 Jul 31.

PMID:
17666462
9.

The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study.

Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM; PROactive Investigators.

J Am Coll Cardiol. 2007 May 1;49(17):1772-80. Epub 2007 Apr 16.

10.

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J; PROactive Investigators.

Lancet. 2005 Oct 8;366(9493):1279-89.

11.

Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study.

Solomon SD, Skali H, Bourgoun M, Fang J, Ghali JK, Martelet M, Wojciechowski D, Ansmite B, Skards J, Laks T, Henry D, Packer M, Pfeffer MA; OVERTURE Investigators.

Am Heart J. 2005 Aug;150(2):257-62.

PMID:
16086927
12.

The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study.

Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S, Bossini A, Fagard R, Gil-Extremera B, Laks T, Kobalava Z, Sarti C, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Birkenhäger WH; Systolic Hypertension in Europe Investigators.

Arch Intern Med. 2002 Oct 14;162(18):2046-52. Erratum in: Arch Intern Med. 2003 Jan 27;163(2):241..

PMID:
12374512
13.

How well can blood pressure be controlled? Progress report on the Systolic Hypertension in Europe Follow-Up Study (Syst-Eur 2).

Thijs L, Staessen JA, Beleva S, Birkenhäger WH, Bulpitt CJ, Celis H, Fletcher AE, Kermova R, Leonetti G, Laks T, Mantov S, Nachev C, Sarti C, Tuomilehto J, Fagard RH; On behalf of the Systolic Hypertension in Europe Investigators .

Curr Control Trials Cardiovasc Med. 2001 Oct 18;2(6):298-306.

14.

Alarmingly high occurrence and case fatality of acute coronary heart disease events in Estonia: results from the Tallinn AMI register 1991-94.

Laks T, Tuomilehto J, Jõeste E, Mäeots E, Salomaa V, Palomäki P, Pullisaar O, Karu K, Torppa J.

J Intern Med. 1999 Jul;246(1):53-60.

15.

Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial.

Forette F, Seux ML, Staessen JA, Thijs L, Birkenhäger WH, Babarskiene MR, Babeanu S, Bossini A, Gil-Extremera B, Girerd X, Laks T, Lilov E, Moisseyev V, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Fagard R.

Lancet. 1998 Oct 24;352(9137):1347-51.

PMID:
9802273
16.

Correlates of cognitive status of old patients with isolated systolic hypertension: the Syst-Eur Vascular Dementia Project.

Seux ML, Thijs L, Forette F, Staessen JA, Birkenhäger WH, Bulpitt CJ, Girerd X, Jääskivi M, Vanhanen H, Kivinen P, Yodfat Y, Vänskä O, Antikainen R, Laks T, Webster JR, Hakamäki T, Lehtomäki E, Lilov E, Grigorov M, Janculova K, Halonen K, Kohonen-Jalonen P, Kermowa R, Nachev C, Tuomilehto J.

J Hypertens. 1998 Jul;16(7):963-9.

PMID:
9794736
17.

Subgroup and per-protocol analysis of the randomized European Trial on Isolated Systolic Hypertension in the Elderly.

Staessen JA, Fagard R, Thijs L, Celis H, Birkenhäger WH, Bulpitt CJ, de Leeuw PW, Fletcher AE, Babarskiene MR, Forette F, Kocemba J, Laks T, Leonetti G, Nachev C, Petrie JC, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Zanchetti A.

Arch Intern Med. 1998 Aug 10-24;158(15):1681-91.

PMID:
9701103
18.

Therapy in old patients with isolated systolic hypertension: fourth progress report on the Syst-Eur trial.

Antikainen R, Tuomilehto J, Thijs L, Vanhanen H, Sarti C, Birkenhäger W, Arabidze G, Fagard R, Grigorow M, Jankulova K, Jääskivi M, Kohonen-Jalonen P, Laks T, Lazebnic L, Mantova S, Nachev C, Kermova P, Vänskä O, Yodfat Y, Bulpitt CJ, Staessen JA.

J Hum Hypertens. 1997 May;11(5):263-9.

PMID:
9205931
19.

Acute myocardial infarction in Estonia: first results from the Tallinn AMI Register.

Laks T, Tuomilehto J, Joeste E, Mäeots E, Pullisaar O, Salomaa V, Viidebaum T, Palomäki P, Karu K, Torppa J.

J Clin Epidemiol. 1996 May;49(5):573-9.

PMID:
8636731
20.

Ambulatory monitoring uncorrected for placebo overestimates long-term antihypertensive action. Systolic Hypertension in Europe (SYST-EUR) Trial Investigators.

Staessen JA, Thijs L, Bieniaszewski L, O'Brien ET, Palatini P, Davidson C, Dobovisek J, Jääskivi M, Laks T, Lehtonen A, Vanhanen H, Webster J, Fagard R.

Hypertension. 1996 Mar;27(3 Pt 1):414-20.

Supplemental Content

Loading ...
Support Center